@article{0f2539a5485a4eaea72104aea37b0178,
title = "Eltrombopag for chronic immune thrombocytopenia - Authors' reply",
author = "Gregory Cheng and Saleh, \{Mansoor N.\} and Claus Marcher and Manuel Aivado and Andres Brainsky and Bussel, \{James B.\}",
note = "Funding Information: The RAISE study was sponsored by GlaxoSmithKline. GC reports receiving research support and lecture fees from GlaxoSmithKline. MNS reports receiving lecture fees from Bristol-Myers Squibb and GlaxoSmithKline, and consulting fees from GlaxoSmithKline. CM reports participating in an advisory board for GlaxoSmithKline. MA and AB are employees of GlaxoSmithKline. JBB reports receiving research support from Amgen, Cangene, Eisai, Genzyme, GlaxoSmithKline, Immunomedics, Ligand, and Sysmex; having equity ownership in Amgen and GlaxoSmithKline; participating in the speaker's bureau programme for Scienta; and participating in advisory boards for Amgen, Eisai, GlaxoSmithKline, Ligand, and Shionogi.",
year = "2011",
doi = "10.1016/S0140-6736(11)60810-6",
language = "English (UK)",
volume = "377",
pages = "1919--1920",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier BV",
number = "9781",
}